CD44 and posterior cortical atrophy: The first preclinical study of miR-34a in PCa was back in 2011, when our group demonstrated that systemic delivery of miR-34a reduced tumor burden and lung metastasis by targeting CD44 in orthotopic PC-3 and LAPC9 xenografts [15].